{"schema_version":"secwatch.filing_event.v1","accession":"0000075252-23-000050","form_type":"8-K","ticker":"ACH","cik":"0000075252","company_name":"ACCENDRA HEALTH INC/VA/","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.950354+00:00","generated_at":"2026-06-08T22:52:27.762887+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Owens & Minor Q3 revenue up 3.8% to $2.59B; adjusted EPS $0.44, debt cut $188M","bullets":["Revenue $2.59B vs $2.497B in Q3 2022, driven by Patient Direct and Medical Distribution growth.","GAAP net loss per share $(0.08); adjusted net income per share $0.44.","Total debt paydown of $188M; net debt reduced by $117M.","Patient Direct outperformed market; Medical Distribution posted mid-single digit growth.","Operating Model Realignment Program delivered economic benefits; cautious on long-term PPE trajectory."],"urls":{"canonical":"https://secwatch.observer/filing/0000075252-23-000050","json":"https://secwatch.observer/filing/0000075252-23-000050.json","markdown":"https://secwatch.observer/filing/0000075252-23-000050.md","text":"https://secwatch.observer/filing/0000075252-23-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/75252/000007525223000050/0000075252-23-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/75252/000007525223000050/omi-20231103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:52:27.762887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"160b1404548f8507d1d0103ac7a9d0f076d7fb0c","claim":"ACCENDRA HEALTH INC/VA/ reported nine months ended September 30, 2023 results: revenue $7,678.","evidence_excerpt":"YTD YTD ($ in millions, except per share data) 3Q23 3Q22 2023 2022 Revenue $2,592 $2,497 $7,678 $7,404 Operating income, GAAP $23.8 $60.2 $44.5 $196.4","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/75252/000007525223000050/0000075252-23-000050-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2023"},{"label":"Revenue","value":"$7,678"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"cfefc3594d4804e23322be328cb1f19cee309735","claim":"ACCENDRA HEALTH INC/VA/ reported third quarter ended September 30, 2023 results: revenue $2.59 billion, net income Net loss per common share of $(0.08), EPS $(0.08).","evidence_excerpt":"2023 – Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the third quarter ended September 30, 2023. Third Quarter Key Highlights: • Consolidated revenue of $2.59 billion • Net loss per common share of $(0.08) and adjusted net income per common share of $0.44 • $188 million in total debt pay down and $117 million reduction in net debt “Our","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/75252/000007525223000050/0000075252-23-000050-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$2.59 billion"},{"label":"Net income","value":"Net loss per common share of $(0.08)"},{"label":"EPS","value":"$(0.08)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}